Fezakinumab
Monoclonal antibody
N
Y (what is this?) (verify) Fezakinumab is a human monoclonal antibody against interleukin-22,[1] designed for the treatment of psoriasis and rheumatoid arthritis.[2]
Research and development
Wyeth discovered and initially developed the drug, and clinical development continued after that company was acquired by Pfizer. Fezakinumab, in combination with methotrexate, completed a phase II trial in rheumatoid arthritis,[3] but data were not released. A small phase II trial of fezakinumab showed significant improvement in the Scoring Atopic Dermatitis (SCORAD) score for patients with severe atopic dermatitis.[4]
References
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab" (PDF). American Medical Association. Retrieved 2017-06-07.
- ^ "Pfizer Pipeline" (PDF). 28 February 2011. Archived from the original (PDF) on 2011-09-04. Retrieved 2012-09-25.
- ^ "Emerging Parenteral Biologic Therapies for Rheumatoid Arthritis". Living Medical eTextbook - Rheumatology - Projects In Knowledge. p. 4. Archived from the original on 24 January 2018. Retrieved 2017-06-07.
- ^ Richardson B. "Atopic dermatitis: fezakinumab shows benefit in severe disease". quantiamd.univadis.com. Aptus Health. Archived from the original on 25 January 2018. Retrieved 24 January 2018.
- v
- t
- e
Monoclonal antibodies for the immune system
| Human | |
|---|---|
| Humanized | |
| Veterinary |
| Mouse |
|
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
